Skip to content

Ardelyx ARDX Net Investment in Lease

Net Investment in Lease at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.53B+79.5%
Enterprise value$1.71B+74.8%
P/S3.6×+1.2×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%
Net margin-13.6%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-39.5%
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Ardelyx’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's net investment in lease?
Ardelyx (ARDX) reported net investment in lease of $4.43M in Q1 2026.
How has Ardelyx's net investment in lease changed year-over-year?
Ardelyx's net investment in lease increased by 20.8% year-over-year, from $3.67M to $4.43M.
What is the long-term trend for Ardelyx's net investment in lease?
Over 5 years (2020 to 2025), Ardelyx's net investment in lease has grown at a 16.1% compound annual growth rate (CAGR), from $2.27M to $4.8M.